Spots Global Cancer Trial Database for immunotherapy
Every month we try and update this database with for immunotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | NCT05205408 | Advanced Solid ... | Oncolytic Virus... | 18 Years - | First Affiliated Hospital Bengbu Medical College | |
| Serial Testing To Assess Cognitive Function In Cancer | NCT06160700 | Cancer | Montreal Cognit... | 18 Years - | Indiana University | |
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | NCT04172506 | Solid Tumor Lung Cancer HCC | AK105 | 18 Years - 75 Years | Akeso | |
| TEIPP Immunotherapy in Patients With NSCLC | NCT05898763 | Non Small Cell ... | TEIPP24 (LRPAP7... | 18 Years - | Erasmus Medical Center | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04435197 | Esophageal Squa... | Pembrolizumab I... | 18 Years - 75 Years | Ruijin Hospital | |
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma | NCT02946138 | Hepatocellular ... | carbon-ion radi... | 18 Years - 80 Years | Shanghai Proton and Heavy Ion Center | |
| Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC | NCT05418660 | Non-small Cell ... | Immunotherapy | 18 Years - | University of Milano Bicocca | |
| Candin for the Treatment of Common Warts | NCT05889845 | Common Warts (V... | Candin, Intrade... Placebo | 12 Years - | Nielsen BioSciences, Inc. | |
| Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors | NCT00640796 | Leukemia, Myelo... Leukemia, Lymph... Juvenile Myelom... T-cell Lymphobl... Myelodysplastic... | Haploidentical ... Chemotherapy CliniMACS | - 18 Years | St. Jude Children's Research Hospital | |
| ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | NCT03003637 | Immunotherapy Head and Neck N... | Nivolumab Ipilimumab | 18 Years - | The Netherlands Cancer Institute | |
| Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | NCT04957511 | Gynecologic Can... Immunotherapy Gut Microbiome | 18 Years - | Viome | ||
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | NCT04037462 | Non-Small Cell ... Immunotherapy | Dexamthasone | 18 Years - | VA Office of Research and Development | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells | NCT03242603 | Neuroblastoma R... | Anti-GD2 in com... | 6 Months - 25 Years | National University Hospital, Singapore | |
| Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | NCT05797493 | Small Cell Lung... | Atezolizumab | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | NCT00960115 | Non-small Cell ... | Tecemotide (L-B... Single low dose... Placebo Saline | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | NCT04220944 | Hepatic Carcino... | Sintilimab Microwave Ablat... TACE | 18 Years - 80 Years | Shanghai Zhongshan Hospital | |
| Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial | NCT05382741 | Colorectal Canc... No Evidence of ... | Durvalumab Inje... Regorafenib 30 ... | 18 Years - | Ospedale Policlinico San Martino | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC. | NCT05117775 | Head and Neck C... | No intervention... | 18 Years - | Savana Research | |
| Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients | NCT01308294 | Melanoma | 2 vaccine injec... 2 vaccine injec... 2 "vaccine inje... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) | NCT05178472 | Hematopoietic a... Malignant Solid... Metastatic Mali... | Immunotherapy Stereotactic Ra... Vertebroplasty | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| DC Vaccine for Patients With Ductal Carcinoma In Situ | NCT02061332 | Breast Cancer DCIS | HER-2 Pulsed De... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy | NCT04924374 | Lung Cancer | Microbiota Tran... anti PD1 therap... | 18 Years - | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | NCT04776447 | Lung Diseases Carcinoma, Non-... Stage IIIA Non-... Stage IIIB Non-... Respiratory Tra... Carcinoma Bronc... Thoracic Neopla... | Carboplatin Placlitaxel Atezolizumab | 18 Years - 75 Years | Fundación GECP | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer | NCT00298298 | Non-Small Cell ... | L-Vax: Autologo... | - | AVAX Technologies | |
| Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC | NCT05516589 | Head and Neck S... | Nab-paclitaxel Cisplatin Tislelizumab Afatinib | 18 Years - | West China Hospital | |
| Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | NCT06229041 | Rectal Cancer | Camrelizumab ＋I... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | NCT04670445 | Stage IV Melano... Advanced Lung C... Stage IV Non-Sm... Unresectable No... Unresectable St... Small Cell Lung... Stage IV Merkel... Stage IV Cutane... Stage IV Basal ... Stage IV Breast... Stage IV Colore... Stage IV Gastri... Stage IV Esopha... Stage IV Hepato... Stage IV Renal ... Stage IV Bladde... Stage IV Head a... Stage IV Cervic... Stage IV Endome... Stage IV Mesoth... Immunotherapy Immune Checkpoi... | Educational Vid... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy | NCT06414304 | Colorectal Canc... Colorectal Canc... MSI-H Colorecta... dMMR Colorectal... Cancer Colon Adenocarc... | 18 Years - | OncoAtlas LLC | ||
| Open Label Immunotherapy Trial for Ovarian Cancer | NCT03556566 | Ovarian Cancer | Tableted vaccin... | 18 Years - 65 Years | Immunitor LLC | |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | NCT06119217 | Pancreatic Canc... | TTX-030, nab-pa... TTX-030, budiga... Nab-Paclitaxel ... | 18 Years - | Trishula Therapeutics, Inc. | |
| Durvalumab Long-Term Safety and Efficacy Study | NCT04078152 | Solid Tumor | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma | NCT04921995 | Recurrent Nasop... Unresectable Na... Chemotherapy Ef... Immunotherapy Stereotactic Bo... | Tislelizumab | 15 Years - 90 Years | Fudan University | |
| Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer | NCT05479240 | Immunotherapy | Tislelizumab Capecitabine oxaliplatin short-range rad... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy | NCT04605146 | Melanoma Lung Cancer Renal Cancer | Tele-monitoring | 18 Years - | Hospices Civils de Lyon | |
| SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | NCT04480372 | Malignant Pleur... Non-small Cell ... | Gemcitabine Atezolizumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer | NCT04779489 | Bladder Cancer | personalized ul... | 18 Years - | University of Texas Southwestern Medical Center | |
| Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | NCT05652673 | Melanoma Stage ... Melanoma Stage ... Immunotherapy Toxicity, Drug | nivolumab | 18 Years - | Erasmus Medical Center | |
| Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | NCT01216436 | Metastatic Mela... | Vaccination wit... | 18 Years - | Duke University | |
| EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC) | NCT00879866 | Lung Cancer Non Small Cell ... | EMD 521873 | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | NCT03570619 | Metastatic Cast... Metastatic Canc... Solid Tumor | Nivolumab Ipilimumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | NCT03666273 | Advanced Solid ... Head and Neck S... | Bapotulimab (BA... Bapotulimab (BA... | 18 Years - | Bayer | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 | NCT03233828 | Melanoma (Skin) Melanoma in Sit... | Aldesleukin Saline | 18 Years - 80 Years | Nova Scotia Health Authority | |
| Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | NCT04110093 | Colorectal Canc... Immunotherapy | Regorafenib and... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | NCT03927222 | Glioblastoma | Human CMV pp65-... Temozolomide Tetanus-Diphthe... GM-CSF 111-Indium-labe... | 18 Years - | Duke University | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | NCT03453892 | Metastatic Canc... | Nivolumab Pembrolizumab Radiotherapy Ipilimumab | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | NCT05860374 | Sarcoma Carcinoma Breast Cancer Pancreatic Canc... Colorectal Canc... Gastric Cancer Liver Cancer Lung Cancer Gynecologic Can... | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | NCT04220892 | High Grade Glio... | Pembrolizumab Pemetrexed Abemaciclib | 18 Years - | Saint John's Cancer Institute | |
| Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma | NCT00200577 | Melanoma | TIL + IL2 | - 75 Years | Nantes University Hospital | |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | NCT04909775 | Muscle-Invasive... | Tislelizumab Cisplatin Gemcitabine | 18 Years - 75 Years | Ruijin Hospital | |
| An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | NCT05225844 | Gastrointestina... Immunotherapy Targeted Therap... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Harbin Medical University | |
| Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | NCT04014530 | Colorectal Canc... Endometrium Can... | Ataluren + Pemb... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 | NCT05593458 | Locally Advance... | Oxaliplatin by ... SOX neoadjuvant Sintilimab neoa... gastrectomy plu... SOX adjuvant, S... Sintilimab adju... | 18 Years - 75 Years | Zhejiang University | |
| Pembrolizumab + Idelalisib for Lung Cancer Study | NCT03257722 | Non Small Cell ... Metastasis Recurrence | Pembrolizumab Idelalisib | 18 Years - | Augusta University | |
| Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | NCT01341496 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Epigenetically ... Cyclophosphamid... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | NCT06089369 | Hepatocellular ... | Sintilimab (9 c... Sintilimab (18 ... Active surveill... | 18 Years - 75 Years | Tongji Hospital | |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) | NCT02999087 | HNSCC | Cetuximab avelumab Cisplatin IMRT | 18 Years - 80 Years | Groupe Oncologie Radiotherapie Tete et Cou |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
